MD Anderson and HealthEx announce collaboration to develop new platform to give patients direct control of data access
Â鶹ӳ» MD Anderson Cancer Center and HealthEx today announced a strategic collaboration aimed at developing tools for streamlining the patient consent process while also creating more transparency and control for patients in how their data is used. Â
As part of this collaboration, MD Anderson and HealthEx will work together for continued development and future implementation of HealthEx’s artificial...
AACR: HER2 targeted therapy shows promise in previously treated lung cancers
Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.Â
...
...
MD Anderson researchers develop novel antibody-toxin conjugate
Researchers at Â鶹ӳ» MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate...
MD Anderson, the Oden Institute and TACC announce funding for six new collaborative cancer projects
Â鶹ӳ» MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing Center (TACC) at Â鶹ӳ» announced funding today for six cancer research projects as part of the Joint Center for Computational Oncology.
Launched in 2020, the collaborative effort aims to accelerate breakthroughs addressing unmet needs for cancer patients by combining...
Funda Meric-Bernstam, M.D., elected to National Academy of Medicine
Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics at Â鶹ӳ» MD Anderson Cancer Center, has been elected...
MD Anderson Research Highlights Special Edition: ASTRO 2024
Â鶹ӳ» MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Allison Institute and Institute for Data Science in Oncology blend spatial biology efforts by appointing new member
The James P. Allison Instituteâ„¢ and the Institute for Data Science in Oncology  (IDSO) at Â鶹ӳ» MD Anderson Cancer...
ESMO: Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human trial
ABSTRACT: 606O
BARCELONA, Spain – The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety...
MD Anderson and Rice launch initiative to advance cancer-focused operations research
Â鶹ӳ» MD Anderson Cancer Center and Rice University today announced the launch of the Center for Operations Research in...
Study supports precision radiation therapy in lung cancer
Results from a new study led by researchers at Â鶹ӳ» MD Anderson Cancer Center support standard use of the more precise...